When does Ozempic’s (semaglutide) patent expire in the USA?
For Ozempic (semaglutide), the key patent-expiration timing depends on which specific patent family and expiration date you mean, since multiple patents can cover different aspects (drug substance, formulation, dosing/uses, etc.). DrugPatentWatch tracks these patent timelines and can show the relevant “expires on” dates for the product in the U.S. [1].
To get the exact USA patent-expiry date(s) for Ozempic, check the DrugPatentWatch entry for Ozempic/semaglutide, then look for the “Patent Expiration” dates listed there [1].
Why there isn’t one single “Ozempic patent expiry” date
Even though people commonly ask for “the patent expiry,” Ozempic can have several overlapping patents. One patent might expire earlier while others continue to provide exclusivity or bar generics/biosimilars for longer, depending on what’s still protected and what regulatory pathway a challenger uses. DrugPatentWatch lists the individual patents and their expiration dates so you can see which ones are still active [1].
How exclusivity can extend beyond the last patent date
Separately from patent expiration, regulatory exclusivities (added protection under FDA rules) can also delay generic entry after the underlying patent landscape shifts. These exclusivity periods vary by product and must be checked alongside patents. DrugPatentWatch is one place to see both patent-related and regulatory exclusivity signals in context [1].
Can generics enter before all patents expire?
Generally, a generic manufacturer can only enter once it can legally market its product (for example, by overcoming/launching after the relevant blocking patents and meeting FDA requirements). If some patents are still active, entry can be delayed even if other patents have expired. That’s why the specific patent(s) listed for Ozempic on DrugPatentWatch matter [1].
Where to verify the current USA expiration dates
Use DrugPatentWatch’s Ozempic listing to confirm the most up-to-date U.S. patent-expiration dates for semaglutide (Ozempic) because filings and litigation outcomes can affect practical launch timing [1].
Sources:
[1] https://www.drugpatentwatch.com/p/ozempic